Would you use a PARP inhibitor as treatment for recurrent platinum-sensitive ovarian cancer with a RAD51 (or other moderate-penetration HRD germline) mutation?

Community
Company
News
Contact Us
Sign in

Topics: Gynecologic Cancers • Ovarian Cancer

Would your recommendation change if the patient was platinum-resistant?

Answer from: at Community Practice

Of course

17959

Related Questions

Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?

How do you counsel patients with homologous recombination repair proficient tumors already on niraparib maintenance therapy, prior to the FDA restriction?

How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?

What toxicities related to mirvetuximab have you seen in your patients and how have you managed them?

Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?

Would you recommend SBRT in the adjuvant settings for a solitary metastasis focus in the abdominal wall resected to R1 in a young and healthy patient with clear cell ovarian cancer?

Given the platinum drug shortage and the recently presented NOW trial, would you consider PARP inhibitor use in place of platinum-based chemotherapy for advanced ovarian cancer?

In a patient with an HR-proficient stage III high-grade serous ovarian cancer s/p R0 primary debulking surgery for whom you are not considering bevacizumab in addition to chemotherapy, would you consider IP chemotherapy?

Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?

How would you approach adjuvant therapy for a patient who was diagnosed with surgically staged and completely resected stage II high-grade serous ovarian cancer while she prepared for neoadjuvant chemoradiation for rectal cancer?